ELErik Larsen

Erik Larsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Erik Larsen has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of vocal biomarkers in detecting cognitive impairment: interim findings from US and Indian populations

    by Erik Larsen, Olivia Murton, Xinyu Song, Erica Weiss, Ayers Emmeline, Jessica Zwerling, Veena Sharath, Soumya Jacob, Alben Sigamani, V.G. Pradeep, et al.

    Background: Vocal biomarkers are emerging as potentially meaningful health indicators in multiple domains, including cognition. Because voice‐enabled devices are widespread, automated vocal analysis could become a useful modality for early detection and monitoring of cognitive impairment. To assess the efficacy of vocal biomarkers in identifying cognitive impairment we evaluated prosodic speech features on vocal tasks in a research cohort from Kerala, India, and a referral cohort from the Montefiore‐Einstein Center for the Aging Brain in the Bronx, NY.Methods: 157 participants (38% female, mean age 67 (4.9)) in India, and 57 participants (65% female, mean age 76 (6.3)) in NY completed voice protocols and cognitive screening (Addenbrooke's Cognitive Examination‐III in India, mean 81 (13); Blessed Information Memory Concentration Test in NY, mean 6.0 (3.7)). Prosodic speech features on vocal tasks with low and high mental effort were compared to performance on cognitive screening. Speech feature values were characterized using means and standard deviations, and subgroup distributions were compared using ratio of means, Cohen’s d for effect size, and significance testing using independent sample t‐tests.Results: Mean speech rate across conditions in syllables/minute was 100 (37) for the India and 107 (34) for the US cohort; pause duration in seconds was 0.68 (0.40) and 0.56 (0.33), respectively. Participants with worse performance on cognitive screening exhibited reduced speech rates and increased pause durations—23% variation in the Indian and 4% in the US cohort. Tasks with higher mental effort mirrored these effects, with about 25% variation in both cohorts. Mental effort had medium to large effect size (0.6‐0.9) and was statistically significant (p<0.01), while cognitive impairment achieved similar effect size and statistical significance for the India cohort only.Conclusion: These preliminary findings reinforce the potential of vocal biomarkers, especially speech rate and pause duration, as potential indicators of cognitive impairment in older adults. The results align with our goals to develop accessible vocal biomarker technology and support continued investigation into their utility in clinical and everyday settings, development of predictive analytics, and incorporating these into existing vocal biomarker platforms.

  • Open Access

    Respiratory-Responsive Vocal Biomarker for Asthma Exacerbation Monitoring: Prospective Cohort Study (Preprint)

    by Erik Larsen, Xinyu Song, Dale Joachim, Peter Ch'EN, Samuel Green, Emily Hunt, Savneet Kaur, Robin Nag, Olivia Pisani, Sherron Thomas, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Asthma exacerbations are a significant issue due to poor perception and failure of traditional monitoring techniques to capture real-time changes in respiratory function. There is a need for strategies to enhance recognition and facilitate timely intervention. Objective: To evaluate the efficacy of a respiratory-responsive vocal biomarker (RRVB), accessible via smartphone application, as a convenient real-time tool for monitoring asthma exacerbations and respiratory states. Methods: In this three-month prospective cohort study, 84 asthma patients recorded daily 6-second vocal samples, generating RRVB scores. The RRVB's ability to predict asthma exacerbations and respiratory states (normal function, mild events, exacerbations) was assessed using risk ratios (RR) and confidence intervals (CIs). Respiratory states were defined using peak expiratory flow (PEF) and self-reported wellbeing, with exacerbations identified by a decline in both PEF and wellbeing, and mild events by a decline in one measure. Results: RRVB scores significantly predicted asthma exacerbations, with a risk ratio of 2.15 (95% CI: 1.62-2.85, p < .001), and 3.57 (95% CI: 2.70-4.73, p < .001) using normalized scores adjusted for individual characteristics. However, time-averaged RRVB scores did not significantly correlate with asthma control as measured by the Asthma Control Test (ACT), with a risk ratio of 1.17 (95% CI: 0.96-1.44, p = .12). A total of 58% of participants remained engaged throughout the study, reporting high satisfaction with the tool's usability and perceived benefits for asthma management. Conclusions: This study demonstrates potential enhancements in asthma management through more accessible and continuous monitoring of respiratory function offered by the RRVB tool, which was shown to provide an effective, real-time, and user-friendly approach for detecting potential exacerbations. Clinical Trial: clinicaltrials.gov: NCT05850390


  • Open Access

    Respiratory-Responsive Vocal Biomarker for Asthma Exacerbation Monitoring: Prospective Cohort Study (Preprint)

    by Erik Larsen, Xinyu Song, Dale Joachim, Peter Y Ch'EN, Samuel M Green, Emily Hunt, Savneet Kaur, Robin Nag, Olivia Pisani, Sherron Thomas, et al.

    BACKGROUND Asthma exacerbations remain a major challenge in asthma management, often due to delayed recognition and limitations of conventional monitoring tools such as peak flow meters and symptom questionnaires. These tools are typically effort dependent or retrospective, making them less suited for continuous, real-time monitoring. A novel, smartphone-based respiratory-responsive vocal biomarker (RRVB) may offer an accessible and noninvasive approach for dynamic assessment of respiratory health. This RRVB has previously demonstrated generalizable performance in cross-sectional cohorts across multiple respiratory conditions, including asthma, chronic obstructive pulmonary disease, and COVID-19, in populations spanning India and the United States. This study extended this work by evaluating the real-world, longitudinal performance of the same RRVB tool for daily asthma exacerbation monitoring via smartphones in home settings. OBJECTIVE This study aimed to evaluate the efficacy of the RRVB as a convenient real-time tool for monitoring asthma exacerbations and respiratory states in a real-world, longitudinal setting. METHODS In this prospective cohort study, 84 adult patients with asthma were enrolled from an academic medical center and followed for 90 days. Participants submitted daily 6-second voice samples and conducted peak expiratory flow measurements and surveys, including symptom reports and asthma control assessments. RRVB scores were generated in real time on the app. Asthma states (normal function, mild event, and exacerbation) were defined based on both peak expiratory flow and self-reported well-being. Risk ratios were calculated to assess the predictive validity of RRVB scores for identifying exacerbation events. Engagement was measured via frequency of completed sessions, and participant experience was evaluated through exit surveys. RESULTS RRVB scores significantly stratified asthma states. The risk of experiencing an exacerbation was 2.15 times higher (95% CI 1.62-2.85; P<.001) with elevated RRVB scores and 3.57 times higher (95% CI 2.70-4.73; P<.001) using normalized scores adjusted for individual characteristics. RRVB scores did not significantly correlate with the Asthma Control Test (risk ratio=1.17, 95% CI 0.96-1.44; P=.12), highlighting its role as a momentary signal rather than a proxy for longitudinal control. Engagement was moderate or higher (≥26 total app sessions) in 58% (49/84) of participants. Among survey respondents, 93% (43/46) found the app easy to use, 89% (41/46) reported a positive overall experience, and 87% (40/46) indicated that they would use a similar tool in the future. Fewer participants (32/46, 70%) reported understanding the RRVB scores, suggesting a need for improved score interpretability and user guidance in future implementations. CONCLUSIONS The RRVB tool demonstrated effective real-time detection of asthma exacerbations and dynamic respiratory states, supporting its potential as a noninvasive, user-friendly, and physiologically grounded digital biomarker for asthma monitoring. These findings provide foundational evidence for broader deployment and integration of voice-based tools to support proactive, real-world asthma management.

  • Open Access

    Validating the efficacy and value proposition of mental fitness vocal biomarkers in a psychiatric population: prospective cohort study

    by Erik Larsen, Olivia Murton, Xinyu Song, Dale Joachim, Devon Watts, Flavio Kapczinski, Lindsey Venesky, Gerald Hurowitz

    Background: The utility of vocal biomarkers for mental health assessment has gained increasing attention. This study aims to further this line of research by introducing a novel vocal scoring system designed to provide mental fitness tracking insights to users in real-world settings.Methods: A prospective cohort study with 104 outpatient psychiatric participants was conducted to validate the “Mental Fitness Vocal Biomarker” (MFVB) score. The MFVB score was derived from eight vocal features, selected based on literature review. Participants’ mental health symptom severity was assessed using the M3 Checklist, which serves as a transdiagnostic tool for measuring depression, anxiety, post-traumatic stress disorder, and bipolar symptoms.Results: The MFVB demonstrated an ability to stratify individuals by their risk of elevated mental health symptom severity. Continuous observation enhanced the MFVB’s efficacy, with risk ratios improving from 1.53 (1.09-2.14, p=0.0138) for single 30-second voice samples to 2.00 (1.21-3.30, p=0.0068) for data aggregated over two weeks. A higher risk ratio of 8.50 (2.31-31.25, p=0.0013) was observed in participants who used the MFVB 5-6 times per week, underscoring the utility of frequent and continuous observation. Participant feedback confirmed the user-friendliness of the application and its perceived benefits.Conclusions: The MFVB is a promising tool for objective mental health tracking in real-world conditions, with potential to be a cost-effective, scalable, and privacy-preserving adjunct to traditional psychiatric assessments. User feedback suggests that vocal biomarkers can offer personalized insights and support clinical therapy and other beneficial activities that are associated with improved mental health risks and outcomes.


  • Open Access

    Validating the efficacy and value proposition of Mental Fitness Vocal Biomarkers in a psychiatric population: prospective cohort study

    by Erik Larsen, Olivia Murton, Xinyu Song, Dale Joachim, Devon Watts, Flavio Kapczinski, Lindsey Venesky, Gerald Hurowitz

    This study represents a practical advancement in the application of vocal biomarkers for mental health tracking in real-world settings. Through a prospective cohort study involving 104 participants from an outpatient psychiatric population, we introduced a novel “Mental Fitness Vocal Biomarker” (MFVB) score, derived from eight preselected vocal features supported by literature review. Our findings demonstrate the MFVB’s efficacy in objectively stratifying individuals based on risk for elevated mental health symptom severity using the M3 Checklist for transdiagnostic assessment (depression, anxiety, post-traumatic stress disorder, and bipolar) as reference standard. Continuous observation over time significantly improves efficacy, yielding a risk ratio of 1.53 (1.09-2.14, p=0.0138) for single 30-second voice samples to 2.00 (1.21-3.30, p=0.0068) for 2-week aggregations, depending on MFVB score. Notably, in the highly engaged subgroup (5-6 MFVB uses per week, 38% of participants), a risk ratio of 8.50 (2.31-31.25, p=0.0013) was observed, underscoring the utility of frequent and continuous observation. Participant feedback confirmed the user-friendliness of the application and perceived benefits, highlighting the MFVB’s potential as a cost-effective, scalable, and privacy-preserving adjunct to traditional psychiatric assessments. These results establish that vocal biomarkers are a promising tool for objective mental health tracking in real-world conditions, offering personalized insights into users’ mental well-being as they engage with clinical therapy or other beneficial activities that are associated with improved mental health risks and outcomes.

  • Ototoxicity associated with high‐dose carboplatin for patients with previously treated germ cell tumors

    by Samuel A. Funt, Andrea Knezevic, Kaamilah Wilson, Maria Bromberg, Amy Budnick, Kerri L. O’cOnnor, Deaglan J. McHugh, Erik Larsen, Dean F. Bajorin, Robert J. Motzer, et al.

    Background: High‐dose carboplatin is an essential part of curative high‐dose chemotherapy (HDCT) for patients with previously treated germ cell tumors (GCTs). Although hearing loss (HL) is a known side effect of HDCT, data on its severity and characteristics are limited.Methods: Eligible patients received HDCT for GCTs from 1993 to 2017 and had audiograms before and after HDCT. HL severity was classified by American Speech‐Language‐Hearing Association criteria, and mean change in hearing threshold at each frequency (0.25–8 kHz) was estimated from pre‐ to post‐HDCT and between HDCT cycles.Results: Of 115 patients (median age, 32 years), 102 (89%) received three cycles of HDCT. Of 106 patients with normal hearing to mild HL in the speech frequencies (0.5–4 kHz) before HDCT, 70 (66%) developed moderate to profound HL in the speech frequencies after HDCT. Twenty‐five patients (22%) were recommended for hearing aids after HDCT. Patients with moderate to profound HL isolated to the higher frequencies (6–8 kHz) before HDCT were more likely to develop moderate to profound HL in the speech frequencies after HDCT (94% vs. 61%; p = .01) and to be recommended for hearing aids (39% vs. 18%; p = .05).Conclusions: HL was frequent after HDCT for GCTs, with most patients developing at least moderate HL in the speech frequencies and approximately one in five recommended for hearing aids. Moderate to profound HL isolated to high frequencies at baseline was predictive of more clinically significant hearing impairment after HDCT.Plain Language Summary: Some patients with germ cell tumors, the most common malignancy in adolescent and young adult men, are not cured with standard‐dose chemotherapy and require high‐dose chemotherapy (HDCT). Using detailed hearing assessments of patients receiving HDCT, we found that most patients developed significant hearing loss and that one in five needed hearing aids. Thus, strategies to reduce this side effect are urgently needed, and all patients receiving HDCT should have a hearing test after therapy.


  • Open Access

    Development and Validation of a Respiratory-Responsive Vocal Biomarker–Based Tool for Generalizable Detection of Respiratory Impairment: Independent Case-Control Studies in Multiple Respiratory Conditions Including Asthma, Chronic Obstructive Pulmonary Disease, and COVID-19

    by Savneet Kaur, Erik Larsen, James Harper, Bharat Purandare, Ahmet Uluer, Mohammad Adrian Hasdianda, Nikita Arun Umale, James Killeen, Edward Castillo, Sunit Jariwala

    Background: Vocal biomarker–based machine learning approaches have shown promising results in the detection of various health conditions, including respiratory diseases, such as asthma. Objective: This study aimed to determine whether a respiratory-responsive vocal biomarker (RRVB) model platform initially trained on an asthma and healthy volunteer (HV) data set can differentiate patients with active COVID-19 infection from asymptomatic HVs by assessing its sensitivity, specificity, and odds ratio (OR). Methods: A logistic regression model using a weighted sum of voice acoustic features was previously trained and validated on a data set of approximately 1700 patients with a confirmed asthma diagnosis and a similar number of healthy controls. The same model has shown generalizability to patients with chronic obstructive pulmonary disease, interstitial lung disease, and cough. In this study, 497 participants (female: n=268, 53.9%; <65 years old: n=467, 94%; Marathi speakers: n=253, 50.9%; English speakers: n=223, 44.9%; Spanish speakers: n=25, 5%) were enrolled across 4 clinical sites in the United States and India and provided voice samples and symptom reports on their personal smartphones. The participants included patients who are symptomatic COVID-19 positive and negative as well as asymptomatic HVs. The RRVB model performance was assessed by comparing it with the clinical diagnosis of COVID-19 confirmed by reverse transcriptase–polymerase chain reaction. Results: The ability of the RRVB model to differentiate patients with respiratory conditions from healthy controls was previously demonstrated on validation data in asthma, chronic obstructive pulmonary disease, interstitial lung disease, and cough, with ORs of 4.3, 9.1, 3.1, and 3.9, respectively. The same RRVB model in this study in COVID-19 performed with a sensitivity of 73.2%, specificity of 62.9%, and OR of 4.64 (P<.001). Patients who experienced respiratory symptoms were detected more frequently than those who did not experience respiratory symptoms and completely asymptomatic patients (sensitivity: 78.4% vs 67.4% vs 68%, respectively). Conclusions: The RRVB model has shown good generalizability across respiratory conditions, geographies, and languages. Results using data set of patients with COVID-19 demonstrate its meaningful potential to serve as a prescreening tool for identifying individuals at risk for COVID-19 infection in combination with temperature and symptom reports. Although not a COVID-19 test, these results suggest that the RRVB model can encourage targeted testing. Moreover, the generalizability of this model for detecting respiratory symptoms across different linguistic and geographic contexts suggests a potential path for the development and validation of voice-based tools for broader disease surveillance and monitoring applications in the future.


  • Open Access

    Development and Validation of a Respiratory-Responsive Vocal Biomarker–Based Tool for Generalizable Detection of Respiratory Impairment: Independent Case-Control Studies in Multiple Respiratory Conditions Including Asthma, Chronic Obstructive Pulmonary Disease, and COVID-19 (Preprint)

    by Savneet Kaur, Erik Larsen, James Harper, Bharat Purandare, Ahmet Uluer, Mohammad Adrian Hasdianda, Nikita Arun Umale, James Killeen, Edward Castillo, Sunit Jariwala

    BACKGROUND Vocal biomarker–based machine learning approaches have shown promising results in the detection of various health conditions, including respiratory diseases, such as asthma. OBJECTIVE This study aimed to determine whether a respiratory-responsive vocal biomarker (RRVB) model platform initially trained on an asthma and healthy volunteer (HV) data set can differentiate patients with active COVID-19 infection from asymptomatic HVs by assessing its sensitivity, specificity, and odds ratio (OR). METHODS A logistic regression model using a weighted sum of voice acoustic features was previously trained and validated on a data set of approximately 1700 patients with a confirmed asthma diagnosis and a similar number of healthy controls. The same model has shown generalizability to patients with chronic obstructive pulmonary disease, interstitial lung disease, and cough. In this study, 497 participants (female: n=268, 53.9%; <65 years old: n=467, 94%; Marathi speakers: n=253, 50.9%; English speakers: n=223, 44.9%; Spanish speakers: n=25, 5%) were enrolled across 4 clinical sites in the United States and India and provided voice samples and symptom reports on their personal smartphones. The participants included patients who are symptomatic COVID-19 positive and negative as well as asymptomatic HVs. The RRVB model performance was assessed by comparing it with the clinical diagnosis of COVID-19 confirmed by reverse transcriptase–polymerase chain reaction. RESULTS The ability of the RRVB model to differentiate patients with respiratory conditions from healthy controls was previously demonstrated on validation data in asthma, chronic obstructive pulmonary disease, interstitial lung disease, and cough, with ORs of 4.3, 9.1, 3.1, and 3.9, respectively. The same RRVB model in this study in COVID-19 performed with a sensitivity of 73.2%, specificity of 62.9%, and OR of 4.64 (P<.001). Patients who experienced respiratory symptoms were detected more frequently than those who did not experience respiratory symptoms and completely asymptomatic patients (sensitivity: 78.4% vs 67.4% vs 68%, respectively). CONCLUSIONS The RRVB model has shown good generalizability across respiratory conditions, geographies, and languages. Results using data set of patients with COVID-19 demonstrate its meaningful potential to serve as a prescreening tool for identifying individuals at risk for COVID-19 infection in combination with temperature and symptom reports. Although not a COVID-19 test, these results suggest that the RRVB model can encourage targeted testing. Moreover, the generalizability of this model for detecting respiratory symptoms across different linguistic and geographic contexts suggests a potential path for the development and validation of voice-based tools for broader disease surveillance and monitoring applications in the future.

  • Open Access

    Translational issues in cochlear synaptopathy

    by Ann E. Hickox, Erik Larsen, Michael G. Heinz, Leslie Shinobu, Jonathon P. Whitton